Skip to main content

Morgan Stanley Sticks to Its Buy Rating for Ascendis Pharma (ASND)

Tipranks - Tipranks - Tue Feb 10, 7:46AM CST

In a report released today, Maxwell Skor from Morgan Stanley maintained a Buy rating on Ascendis Pharma, with a price target of $250.00.

Valentine's Day Sale - 70% Off

According to TipRanks, Skor is a 5-star analyst with an average return of 20.8% and a 66.25% success rate. Skor covers the Healthcare sector, focusing on stocks such as Pharvaris, Ascendis Pharma, and Cytokinetics.

In addition to Morgan Stanley, Ascendis Pharma also received a Buy from Bank of America Securities’s Tazeen Ahmad in a report issued on January 30. However, on January 28, TipRanks – xAI reiterated a Hold rating on Ascendis Pharma (NASDAQ: ASND).

See Insiders’ Hot Stocks on TipRanks >>

Based on Ascendis Pharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $213.63 million and a GAAP net loss of $60.99 million. In comparison, last year the company earned a revenue of $57.83 million and had a GAAP net loss of $99.2 million

Read More on ASND:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).